Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21142861 | 1.00 | ALDH1A1 (0.53) | ALDH1A1CXCR4SMN1; SMN2 | |
| SCHEMBL21142867 | 1.00 | ALDH1A1 (0.53) | ALDH1A1CXCR4SMN1; SMN2 | |
| SCHEMBL21145820 | 0.97 | ALDH1A1 (0.50) | ALDH1A1CXCR4SMN1; SMN2 | |
| SCHEMBL21145505 | 0.97 | ALDH1A1 (0.50) | ALDH1A1CXCR4SMN1; SMN2 | |
| SCHEMBL28755707 | 0.82 | — | — | |
| SCHEMBL27175 | 0.80 | — | — | |
| SCHEMBL21624980 | 0.80 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL50228 | 0.80 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL3168987 | 0.80 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL4955809 | 0.80 | ALDH1A1 (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | ALDH1A1 448/4885CXCR4 4244/4885SMN1; SMN2 341/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | ALDH1A1 448/4885CXCR4 4244/4885SMN1; SMN2 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.